Literature DB >> 12015836

Endovascular treatment for poorest-grade subarachnoid hemorrhage in the acute stage: has the outcome been improved?

Joji Inamasu1, Yoshiki Nakamura, Ryoichi Saito, Yoshiaki Kuroshima, Keita Mayanagi, Kiyoshi Ichikizaki.   

Abstract

OBJECTIVE: Patients with poor-grade subarachnoid hemorrhage (SAH) have been considered good candidates for endovascular treatment. The results of treatment of Grade V SAH, the poorest grade, however, have not been fully elucidated.
METHODS: The clinical characteristics and outcome parameters of 22 World Federation of Neurosurgical Societies Grade V SAH patients treated endovascularly in the acute stage between 1998 and 2000 are summarized and compared with those of 18 Grade V SAH patients treated conservatively between 1995 and 1997.
RESULTS: Among the 22 patients treated endovascularly, 8 patients (36.4%) survived. The rate was significantly higher than that of the 18 patients treated conservatively (5.6%), only one of whom survived. The favorable outcome rate, however, was not significantly different between the two groups (4.5% versus 6.0%). Subdivision of both treatment groups according to Glasgow Coma Scale (GCS) score showed that the improved survival among those treated endovascularly was attributable to the improved survival in those with a preprocedural GCS score of 6 but not of 4 or 5.
CONCLUSION: Endovascular treatment of the 22 World Federation of Neurosurgical Societies Grade V SAH patients improved their survival rate but not their favorable outcome rate in comparison with conservative treatment. Further accumulation of clinical data is essential to determine whether endovascular treatment can improve the functional outcome of those with GCS scores of 6 and whether there is no role for endovascular treatment in those with GCS scores of 4 or 5.

Entities:  

Mesh:

Year:  2002        PMID: 12015836     DOI: 10.1097/00006123-200206000-00005

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  7 in total

1.  [Therapeutic hypothermia after traumatic brain injury or subarachnoid hemorrhage. Current practices of German anaesthesia departments in intensive care].

Authors:  S Himmelseher; C Werner
Journal:  Anaesthesist       Date:  2004-12       Impact factor: 1.041

2.  Comparison of Endovascular and Surgical Treatment for Ruptured Cerebral Aneurysms with respect to Short and Long-Term Outcome.

Authors:  K Fukui; O Suzuki; S Ito; M Miyazaki; K Hattori; H Osawa
Journal:  Interv Neuroradiol       Date:  2004-10-22       Impact factor: 1.610

3.  Acute endovascular treatment of ruptured aneurysms in poor-grade patients.

Authors:  M Bergui; G B Bradac
Journal:  Neuroradiology       Date:  2003-12-20       Impact factor: 2.804

Review 4.  Functional Outcome After Poor-Grade Subarachnoid Hemorrhage: A Single-Center Study and Systematic Literature Review.

Authors:  Airton Leonardo de Oliveira Manoel; Ann Mansur; Gisele Sampaio Silva; Menno R Germans; Blessing N R Jaja; Ekaterina Kouzmina; Thomas R Marotta; Simon Abrahamson; Tom A Schweizer; Julian Spears; R Loch Macdonald
Journal:  Neurocrit Care       Date:  2016-12       Impact factor: 3.210

5.  Long-term Functional Outcomes for World Federation of Neurosurgical Societies Grade V Aneurysmal Subarachnoid Hemorrhage after Active Treatment.

Authors:  Kenichi Ariyada; Tomoya Ohida; Keita Shibahashi; Hidenori Hoda; Kazuo Hanakawa; Masahiko Murao
Journal:  Neurol Med Chir (Tokyo)       Date:  2020-07-16       Impact factor: 1.742

6.  Somatosensory and Brainstem Auditory Evoked Potentials Assessed between 4 and 7 Days after Severe Stroke Onset Predict Unfavorable Outcome.

Authors:  Yan Zhang; Ying Ying Su; Shu Ying Xiao; Yi Fei Liu
Journal:  Biomed Res Int       Date:  2015-12-21       Impact factor: 3.411

7.  Outcomes of high-grade aneurysmal subarachnoid hemorrhage patients treated with coiling and ventricular intracranial pressure monitoring.

Authors:  Li-Li Wen; Xiao-Ming Zhou; Sheng-Yin Lv; Jiang Shao; Han-Dong Wang; Xin Zhang
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.